Pregnancy and autoimmune connective tissue diseases

Best Practice and Research: Clinical Rheumatology

Volumn 30, Issue 1, 2016, Pages 63-80

  Marder, Wendy ^a   Littlejohn, Emily A ^a   Somers, Emily C ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antiphospholipid antibody syndrome; Autoimmunity; Myositis; Pregnancy; Rheumatoid arthritis; Scleroderma; Sjogren's syndrome; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLATE MOFETIL; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TACROLIMUS; TUMOR NECROSIS FACTOR INHIBITOR;

ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; BREAST FEEDING; CONCEPTION; CONNECTIVE TISSUE DISEASE; CONTRACEPTION; DRUG CONTRAINDICATION; FOLLOW UP; HUMAN; LUPUS ERYTHEMATOSUS; LUPUS ERYTHEMATOSUS NEPHRITIS; MATERNAL DISEASE; MYOSITIS; NEWBORN DISEASE; PREGNANCY; PREGNANCY OUTCOME; PREPREGNANCY CARE; PRIORITY JOURNAL; PUERPERIUM; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; COMPLICATION; FEMALE; IMMUNOLOGY; PREGNANCY COMPLICATION;

AUTOIMMUNE DISEASES; CONNECTIVE TISSUE DISEASES; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; RISK FACTORS;

EID: 84977614580     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2016.05.002     Document Type: Review

References (143)

1. [1] Cooper, G.S., Bynum, M.L.K., Somers, E.C., Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun 33 (2009), 197–207, 10.1016/j.jaut.2009.09.008.
2. [2] Clowse, M.E.B., Magder, L.S., Witter, F., et al. Early risk factors for pregnancy loss in lupus. Obstet Gynecol 107 (2006), 293–299, 10.1097/01.AOG.0000194205.95870.86.
3. Clowse, M.E.B., Jamison, M., Myers, E., et al. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol 199 (2008), 1–12, 10.1016/j.ajog.2008.03.012.
4. [4] Nodler, J., Moolamalla, S.R., Ledger, E.M., et al. Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: analysis of a population-based hospital dataset. BMC Pregnancy Childbirth, 9, 2009, 11, 10.1186/1471-2393-9-11.
5. [5] Clark, C.A., Spitzer, K.A., Laskin, C.A., Decrease in pregnancy loss rates in patients with systemic lupus erythematosus over a 40-year period. J Rheumatol 32 (2005), 1709–1712.
6. [6] Clowse, M.E.B., Magder, L.S., Witter, F., et al. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 52 (2005), 514–521, 10.1002/art.20864.
7. [7] Del Junco, D.J., Annegers, J.F., Coulam, C.B., et al. The relationship between rheumatoid arthritis and reproductive function. Br J Rheumatol, 28(Suppl. 1), 1989, 33 discussion 42–5.
8. [8] Hazes, J.M., Dijkmans, B.A., Vandenbroucke, J.P., et al. Pregnancy and the risk of developing rheumatoid arthritis. Arthritis Rheum 33 (1990), 1770–1775.
9. [9] Spector, T.D., Roman, E., Silman, A.J., The pill, parity, and rheumatoid arthritis. Arthritis Rheum 33 (1990), 782–789.
10. [10] Guthrie, K.A., Dugowson, C.E., Voigt, L.F., et al. Does pregnancy provide vaccine-like protection against rheumatoid arthritis?. Arthritis Rheum 62 (2010), 1842–1848, 10.1002/art.27459.
11. [11] Jørgensen, K.T., Pedersen, B.V., Jacobsen, S., et al. National cohort study of reproductive risk factors for rheumatoid arthritis in Denmark: a role for hyperemesis, gestational hypertension and pre-eclampsia?. Ann Rheum Dis 69 (2010), 358–363, 10.1136/ard.2008.099945.
12. [12] Hernández Avila, M., Liang, M.H., Willett, W.C., et al. Reproductive factors, smoking, and the risk for rheumatoid arthritis. Epidemiology 1 (1990), 285–291.
13. [13] Karlson, E.W., Mandl, L.A., Hankinson, S.E., et al. Do breast-feeding and other reproductive factors influence future risk of rheumatoid arthritis? Results from the Nurses’ Health Study. Arthritis Rheum 50 (2004), 3458–3467, 10.1002/art.20621.
14. [14] Heliövaara, M., Aho, K., Reunanen, A., et al. Parity and risk of rheumatoid arthritis in Finnish women. Br J Rheumatol 34 (1995), 625–628.
15. [15] Brun, J.G., Nilssen, S., Kvåle, G., Breast feeding, other reproductive factors and rheumatoid arthritis. A prospective study. Br J Rheumatol 34 (1995), 542–546.
16. [16] Merlino, L.A., Cerhan, J.R., Criswell, L.A., et al. Estrogen and other female reproductive risk factors are not strongly associated with the development of rheumatoid arthritis in elderly women. Semin Arthritis Rheum 33 (2003), 72–82, 10.1016/S0049-0172(03)00084-2.
17. [17] Marder, W., Somers, E.C., Is pregnancy a risk factor for rheumatic autoimmune diseases?. Curr Opin Rheumatol 26 (2014), 321–328, 10.1097/BOR.0000000000000047.
18. [18] Khashan, A.S., Kenny, L.C., Laursen, T.M., et al. Pregnancy and the risk of autoimmune disease. PLoS One, 6, 2011, e19658, 10.1371/journal.pone.0019658.
19. [19] Oka, M., Effect of pregnancy on the onset and course of rheumatoid arthritis. Ann Rheum Dis 12 (1953), 227–229.
20. [20] Silman, A., Kay, A., Brennan, P., Timing of pregnancy in relation to the onset of rheumatoid arthritis. Arthritis Rheum 35 (1992), 152–155.
21. [21] Lansink, M., de Boer, A., Dijkmans, B.A., et al. The onset of rheumatoid arthritis in relation to pregnancy and childbirth. Clin Exp Rheumatol 11 (1993), 171–174.
22. [22] Cooper, G.S., Gilbert, K.M., Greidinger, E.L., et al. Recent advances and opportunities in research on lupus: environmental influences and mechanisms of disease. Environ Health Perspect 116 (2008), 695–702, 10.1289/ehp.11092.
23. [23] Somers, E.C., Thomas, S.L., Smeeth, L., et al. Incidence of systemic lupus erythematosus in the United Kingdom, 1990-1999. Arthritis Rheum 57 (2007), 612–618, 10.1002/art.22683.
24. [24] Somers, E.C., Marder, W., Cagnoli, P., et al. Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program. Arthritis Rheumatol (Hoboken, NJ) 66 (2014), 369–378, 10.1002/art.38238.
25. Chakravarty, E.F., Nelson, L., Krishnan, E., Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 54 (2006), 899–907, 10.1002/art.21663.
26. [26] Jakobsen, I.M., Helmig, R.B., Stengaard-Pedersen, K., Maternal and foetal outcomes in pregnant systemic lupus erythematosus patients: an incident cohort from a stable referral population followed during 1990-2010. Scand J Rheumatol 44 (2015), 377–384, 10.3109/03009742.2015.1013982.
27. [27] Buchanan, N.M., Khamashta, M., Kerslake, S., et al. Practical management of pregnancy in systemic lupus erythematosus. Fetal Matern Med Rev, 5, 1993, 223, 10.1017/S0965539500000917.
28. [28] Levy, R., Vilela, V., Cataldo, M., et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 10 (2001), 401–404, 10.1191/096120301678646137.
29. [29] Leroux, M., Desveaux, C., Parcevaux, M., et al. Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study. Lupus, 2015, 1384–1391, 10.1177/0961203315591027.
30. [30] Clowse, M.E.B., Magder, L., Witter, F., et al. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 54 (2006), 3640–3647, 10.1002/art.22159.
31. [31] Derksen, R.H., Bruinse, H.W., de Groot, P.G., et al. Pregnancy in systemic lupus erythematosus: a prospective study. Lupus 3 (1994), 149–155.
32. [32] Buyon, J.P., Kim, M.Y., Guerra, M.M., et al. Predictors of pregnancy outcomes in patients with lupus: a cohort study. Ann Intern Med 163 (2015), 153–163, 10.7326/M14-2235.
33. [33] Schreiber, K., Pregnancies in women with systemic lupus erythematosus and antiphospholipid antibodies. Lupus, 2016, 1–3, 10.1177/0961203315627201.
34. [34] Smyth, A., Oliveira, G.H.M., Lahr, B.D., et al. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 5 (2010), 2060–2068, 10.2215/CJN.00240110.
35. [35] Miyakis, S., Lockshin, M.D., Atsumi, T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 (2006), 295–306, 10.1111/j.1538-7836.2006.01753.x.
36. [36] Wilson, W.A., Gharavi, A.E., Koike, T., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42 (1999), 1309–1311, 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F.
37. [37] Hughes, G.R., The antiphospholipid syndrome: ten years on. Lancet (London, England) 342 (1993), 341–344.
38. [38] Tincani, A., Bazzani, C., Zingarelli, S., et al. Lupus and the antiphospholipid syndrome in pregnancy and obstetrics: clinical characteristics, diagnosis, pathogenesis, and treatment. Semin Thromb Hemost 34 (2008), 267–273, 10.1055/s-0028-1082270.
39. [39] Ruffatti, A., Tonello, M., Visentin, M.S., et al. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatol (Oxford) 50 (2011), 1684–1689, 10.1093/rheumatology/ker139.
40. [40] Ruffatti, A., Calligaro, A., Hoxha, A., et al. Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res (Hoboken) 62 (2010), 302–307, 10.1002/acr.20098.
41. [41] Derksen, R.H.W.M., de Groot, P.G., The obstetric antiphospholipid syndrome. J Reprod Immunol 77 (2008), 41–50, 10.1016/j.jri.2006.12.003.
42. [42] Branch, D.W., Antiphospholipid antibodies and fetal compromise. Thrombosis Res, 2004, 415–418, 10.1016/j.thromres.2004.08.005.
43. [43] Bramham, K., Hunt, B.J., Germain, S., et al. Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus 19 (2010), 58–64, 10.1177/0961203309347794.
44. [44] Lockshin, M.D., Kim, M., Laskin, C.A., et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 64 (2012), 2311–2318, 10.1002/art.34402.
45. [45] Farquharson, R.G., Quenby, S., Greaves, M., Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 100 (2002), 408–413, 10.1016/S0029-7844(02)02165-8.
46. [46] Ziakas, P.D., Pavlou, M., Voulgarelis, M., Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obs Gynecol 115 (2010), 1256–1262, 10.1097/AOG.0b013e3181deba40 pii: r00006250-201006000-00023.
47. [47] Mak, A., Cheung, M.W.-L., Cheak, A.A., et al. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatol (Oxford) 49 (2010), 281–288, 10.1093/rheumatology/kep373.
48. [48] Davis, S.M., Branch, D.W., Thromboprophylaxis in pregnancy: who and how?. Obstet Gynecol Clin North Am 37 (2010), 333–343, 10.1016/j.ogc.2010.02.004.
49. [49] Sciascia, S., Branch, D.W., Levy, R.A., et al. The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. Thromb Haemost 115 (2015), 285–290, 10.1160/TH15-06-0491.
50. [50] Rainsford, K.D., Parke, A.L., Clifford-Rashotte, M., et al. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 23 (2015), 231–269, 10.1007/s10787-015-0239-y.
51. de Man, Y.A., Hazes, J.M.W., van de Geijn, F.E., et al. Measuring disease activity and functionality during pregnancy in patients with rheumatoid arthritis. Arthritis Rheum 57 (2007), 716–722, 10.1002/art.22773.
52. [52] de Man, Y.A., Dolhain, R.J.E.M., van de Geijn, F.E., et al. Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum 59 (2008), 1241–1248, 10.1002/art.24003.
53. [53] De Man, Y.A., Hazes, J.M.W., Van Der Heide, H., et al. Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study. Arthritis Rheum 60 (2009), 3196–3206, 10.1002/art.24914.
54. [54] Bharti, B., Lee, S.J., Lindsay, S.P., et al. Disease severity and pregnancy outcomes in women with rheumatoid arthritis: results from the organization of teratology information specialists autoimmune diseases in pregnancy project. J Rheumatol 42 (2015), 1376–1382, 10.3899/jrheum.140583.
55. [55] Cook, W.A., Letter: Raynaud phenomenon in pregnancy. J Am Med Assoc 235 (1976), 145–146.
56. [56] Chakravarty, E.F., Khanna, D., Chung, L., Pregnancy outcomes in systemic sclerosis, primary pulmonary hypertension, and sickle cell disease. Obstet Gynecol 111 (2008), 927–934, 10.1097/01.AOG.0000308710.86880.a6.
57. [57] Steen, V.D., Medsger, T.A., Fertility and pregnancy outcome in women with systemic sclerosis. Arthritis Rheum 42 (1999), 763–768, 10.1002/1529-0131(199904)42:4<763::AID-ANR21>3.0.CO;2-V.
58. [58] Taraborelli, M., Ramoni, V., Brucato, A., et al. Brief report: successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: an Italian multicenter study. Arthritis Rheum 64 (2012), 1970–1977, 10.1002/art.34350.
59. [59] ARA Subcommittee, Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23 (1980), 581–590.
60. [60] LeRoy, E.C., Medsger, J., Criteria for the classification of early systemic sclerosis. J Rheumatol 28 (2001), 1573–1576.
61. [61] Di Martino, S.J., Myositis and pregnancy. Bermas, B.L., Sammaritano, L.R., (eds.) Contraception and pregnancy in patients with rheumatic disease, 2014, Springer, New York, NY, 185–197, 10.1007/978-1-4939-0673-4.
62. [62] Pinal-Fernandez, I., Selva-O'Callaghan, A., Fernandez-Codina, A., et al. Pregnancy in adult-onset idiopathic inflammatory myopathy’: report from a cohort of myositis patients from a single center. Semin Arthritis Rheum 44 (2014), 234–240, 10.1016/j.semarthrit.2014.05.004.
63. [63] Bohan, A., Peter, J.B., Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292 (1975), 344–347, 10.1056/NEJM197502132920706.
64. [64] Bohan, A., Peter, J.B., Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292 (1975), 403–407, 10.1056/NEJM197502202920807.
65. [65] Shahane, A., Patel, R., The epidemiology of Sjögren's syndrome. Clin Epidemiol, 2014, 247, 10.2147/CLEP.S47399.
66. [66] Hussein, S.Z., Jacobsson, L.T.H., Lindquist, P.G., et al. Pregnancy and fetal outcome in women with primary Sjogren's syndrome compared with women in the general population: a nested case-control study. Rheumatology 50 (2011), 1612–1617, 10.1093/rheumatology/ker077.
67. [67] Takaya, M., Ichikawa, Y., Shimizu, H., et al. Sjögren's syndrome and pregnancy. Tokai J Exp Clin Med 16 (1991), 83–88.
68. [68] Moak, J.P., Barron, K.S., Hougen, T.J., et al. Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela. J Am Coll Cardiol 37 (2001), 238–242, 10.1016/S0735-1097(00)01048-2.
69. [69] Nield, L.E., Silverman, E.D., Taylor, G.P., et al. Maternal anti-Ro and anti-La antibody - associated endocardial fibroelastosis. Circulation 105 (2002), 843–848, 10.1161/hc0702.104182.
70. [70] Buyon, J.P., Winchester, R.J., Slade, S.G., et al. Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children: comparison of enzyme-linked immunosorbent assay and immunoblot for measurement of anti-SS-A/Ro and anti- SS-B/La antibodies. Arthritis Rheum 36 (1993), 1263–1273, 10.1002/art.1780360911.
71. [71] Jaeggi, E.T., Hamilton, R.M., Silverman, E.D., et al. Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block: a single institution's experience of 30 years. J Am Coll Cardiol 39 (2002), 130–137, 10.1016/S0735-1097(01)01697-7.
72. [72] Brito-Zerón, P., Izmirly, P.M., Ramos-Casals, M., et al. Autoimmune congenital heart block: complex and unusual situations. Lupus 25 (2016), 116–128, 10.1177/0961203315624024.
73. [73] Brucato, A., Doria, A., Frassi, M., et al. Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study. Lupus 11 (2002), 716–721, 10.1191/0961203302lu252oa.
74. [74] Buyon, J.P., Hiebert, R., Copel, J., et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 31 (1998), 1658–1666, 10.1016/S0735-1097(98)00161-2.
75. [75] Friedman, D., Duncanson, L., Glickstein, J., et al. A review of congenital heart block. Images Paediatr Cardiol 5 (2003), 36–48.
76. [76] Friedman, D.M., Kim, M.Y., Copel, J.A., et al. Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR interval and dexamethasone evaluation (PRIDE) study. Am J Cardiol 103 (2009), 1102–1106, 10.1016/j.amjcard.2008.12.027.
77. [77] Izmirly, P.M., Saxena, A., Kim, M.Y., et al. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation 124 (2011), 1927–1935, 10.1161/CIRCULATIONAHA.111.033894.
78. [78] Eliasson, H., Sonesson, S.E., Sharland, G., et al. Isolated atrioventricular block in the fetus: a retrospective, multinational, multicenter study of 175 patients. Circulation 124 (2011), 1919–1926, 10.1161/CIRCULATIONAHA.111.041970.
79. Izmirly, P.M., Saxena, A., Sahl, S.K., et al. Assessment of fluorinated steroids to avert progression and mortality in anti-SSA/Ro-associated cardiac injury limited to the fetal conduction system. Ann Rheum Dis, 2015, 208311, 10.1136/annrheumdis-2015-208311.
80. [80] Izmirly, P.M., Costedoat-Chalumeau, N., Pisoni, C.N., et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/ro-antibody - associated cardiac manifestations of neonatal lupus. Circulation 126 (2012), 76–82, 10.1161/CIRCULATIONAHA.111.089268.
81. [81] Saxena, A., Izmirly, P.M., Mendez, B., et al. Prevention and treatment in utero of autoimmune-associated congenital heart block. Cardiol Rev 22 (2014), 263–267, 10.1097/CRD.0000000000000026.
82. [82] Trucco, S.M., Jaeggi, E., Cuneo, B., et al. Use of intravenous gamma globulin and corticosteroids in the treatment of maternal autoantibody-mediated cardiomyopathy. J Am Coll Cardiol 57 (2011), 715–723, 10.1016/j.jacc.2010.09.044.
83. [83] ØStensen, M., Intravenous immunoglobulin does not prevent recurrence of congenital heart block in children of SSA/Ro-positive mothers. Arthritis Rheum 62 (2010), 911–914, 10.1002/art.27317.
84. [84] Hoeper, M.M., Bogaard, H.J., Condliffe, R., et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 62 (2013), D42–D50, 10.1016/j.jacc.2013.10.032.
85. [85] Regitz-Zagrosek, V., Blomstrom Lundqvist, C., Borghi, C., et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy. Eur Heart J 32 (2011), 3147–3197, 10.1093/eurheartj/ehr218.
86. [86] de Jesus, G.R., Mendoza-Pinto, C., de Jesus, N.R., et al. Understanding and managing pregnancy in patients with lupus. Autoimmune Dis, 2015, 2015, 943490, 10.1155/2015/943490.
87. [87] Mok, C.C., Lau, C.S., Wong, R.W., Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 41 (1998), 831–837, 10.1002/1529-0131(199805)41:5<831::AID-ART9>3.0.CO;2–1.
88. [88] Houssiau, F.A., Vasconcelos, C., D'Cruz, D., et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46 (2002), 2121–2131, 10.1002/art.10461.
89. [89] Riskalla, M.M., Somers, E.C., Fatica, R.A., et al. Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. J Rheumatol 30 (2003), 1508–1512.
90. [90] Ginzler, E.M., Dooley, M.A., Aranow, C., et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353 (2005), 2219–2228, 10.1056/NEJMoa043731.
91. [91] Marder, W., McCune, W.J., Wang, L., et al. Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients. Gynecol Endocrinol 28 (2012), 624–627, 10.3109/09513590.2011.650752.
92. [92] Somers, E.C., Marder, W., Christman, G.M., et al. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 52 (2005), 2761–2767, 10.1002/art.21263.
93. [93] Finer, L.B., Zolna, M.R., Declines in unintended pregnancy in the United States, 2008-2011. N Engl J Med 374 (2016), 843–852, 10.1056/NEJMsa1506575.
94. [94] Hayslett, J.P., Maternal and fetal complications in pregnant women with systemic lupus erythematosus. Am J Kidney Dis 17 (1991), 123–126.
95. Sammaritano, L.R., Therapy insight: guidelines for selection of contraception in women with rheumatic diseases. Nat Clin Pract Rheumatol 3 (2007), 273–281, 10.1038/ncprheum0484 quiz 305–6.
96. [96] Kaiser, R., Cleveland, C.M., Criswell, L.A., Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis 68 (2009), 238–241, 10.1136/ard.2008.093013.
97. [97] Petri, M., Kim, M.Y., Kalunian, K.C., et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 353 (2005), 2550–2558, 10.1056/NEJMoa051135.
98. [98] CDC, U.S. medical eligibility criteria for contraceptive use, 2010: adapted from the World Health Organization medical eligibility criteria for contraceptive use. 4th ed., vol. 59(RR04), 2010, 1–6 http://www.cdc.gov/reproductivehealth/unintendedpregnancy/usmec.htm [accessed 01.04.16].
99. Skorpen, C.G., Hoeltzenbein, M., Tincani, A., et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis, 2016, 1–16, 10.1136/annrheumdis-2015-208840.
100. Flint, J., Panchal, S., Hurrell, A., et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatol (Oxford), kev404, 2016, 10.1093/rheumatology/kev404.
101. Flint, J., Panchal, S., Hurrell, A., et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part II: analgesics and other drugs used in rheumatology practice. Rheumatol (Oxford), kev405, 2016, 10.1093/rheumatology/kev405.
102. [102] Østensen, M., Khamashta, M., Lockshin, M., et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther, 8, 2006, 209, 10.1186/ar1957.
103. [103] Clowse, M.E.B., Chapter 36 – pregnancy in women with SLE. 8th ed., 2013, Elsevier Inc, 10.1016/B978-1-4377-1893-5.00036-4.
104. [104] Benediktsson, R., Calder, A.A., Edwards, C.R., et al. Placental 11 beta-hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure. Clin Endocrinol (Oxf) 46 (1997), 161–166.
105. [105] Bramham, K., Thomas, M., Nelson-Piercy, C., et al. First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood 117 (2011), 6948–6951, 10.1182/blood-2011-02-339234.
106. [106] Bermas, B.L., Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy. Curr Opin Rheumatol 26 (2014), 334–340, 10.1097/BOR.0000000000000054.
107. [107] Park-Wyllie, L., Mazzotta, P., Pastuszak, A., et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 62 (2000), 385–392, 10.1002/1096-9926(200012)62:6<385::AID-TERA5>3.0.CO;2-Z.
108. [108] Bykerk, V., Sampalis, J., Esdaile, J.M., et al. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N Engl J Med 324 (1991), 150–154, 10.1056/NEJM199101173240303.
109. [109] Diav-Citrin, O., Blyakhman, S., Shechtman, S., et al. Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study. Reprod Toxicol 39 (2013), 58–62, 10.1016/j.reprotox.2013.04.005.
110. [110] Costedoat-Chalumeau, N., Amoura, Z., Aymard, G., et al. Evidence of transplacental passage of hydroxychloroquine in humans. Arthritis Rheum 46 (2002), 1123–1124, 10.1002/art.10150.
111. [111] Costedoat-Chalumeau, N., Amoura, Z., Duhaut, P., et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 48 (2003), 3207–3211, 10.1002/art.11304.
112. [112] Noviani, M., Wasserman, S., Clowse, M.E.B., Breastfeeding in mothers with systemic lupus erythematosus. Lupus, 2016, 1–7, 10.1177/0961203316629555.
113. [113] Sperber, K., Hom, C., Chao, C.P., et al. Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatr Rheumatol Online J, 7, 2009, 9, 10.1186/1546-0096-7-9.
114. [114] Viktil, K., Engeland, A., Furu, K., Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150 000 pregnant women and expectant fathers. Scand J Rheumatol 41 (2012), 196–201, 10.3109/03009742.2011.626442.
115. [115] Rahimi, R., Nikfar, S., Rezaie, A., et al. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol 25 (2008), 271–275, 10.1016/j.reprotox.2007.11.010.
116. Hernández-Díaz, S., Werler, M.M., Walker, A.M., et al. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol 153 (2001), 961–968, 10.1093/aje/153.10.961.
117. [117] Marder, W., McCune, W.J., Advances in immunosuppressive therapy. Semin Respir Crit Care Med 28 (2007), 398–417, 10.1055/s-2007-985612.
118. [118] Jharap, B., de Boer, N.K.H., Stokkers, P., et al. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut 63 (2014), 451–457, 10.1136/gutjnl-2012-303615.
119. [119] Nguyen, GC, Seow, CH, Maxwell, C, The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology 150 (2016), 734–757.e1, 10.1053/j.gastro.2015.12.003.
120. [120] DeWitte, D.B., Buick, M.K., Cyran, S.E., et al. Neonatal pancytopenia and severe combined immunodeficiency associated with antenatal administration of azathioprine and prednisone. J Pediatr 105 (1984), 625–628.
121. [121] Coté, C.J., Meuwissen, H.J., Pickering, R.J., Effects on the neonate of prednisone and azathioprine administered to the mother during pregnancy. J Pediatr 85 (1974), 324–328.
122. [122] Nørgård, B., Pedersen, L., Christensen, L.A., et al. Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol 102 (2007), 1406–1413, 10.1111/j.1572-0241.2007.01216.x.
123. [123] Matalon, S.T., Ornoy, A., Lishner, M., Review of the potential effects of three commonly used antineoplastic and immunosuppressive drugs (cyclophosphamide, azathioprine, doxorubicin on the embryo and placenta). Reprod Toxicol 18 (2004), 219–230, 10.1016/j.reprotox.2003.10.014.
124. [124] Goldstein, L.H., Dolinsky, G., Greenberg, R., et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol 79 (2007), 696–701, 10.1002/bdra.20399.
125. [125] Marder, W, Ganser, MA, Romero, V, et al. In utero azathioprine exposure and increased utilization of special educational services in children born to mothers with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 65 (2013), 759–766, 10.1002/acr.21888.
126. [126] Webster, P., Wardle, A., Bramham, K., et al. Tacrolimus is an effective treatment for lupus nephritis in pregnancy. Lupus 23 (2014), 1192–1196, 10.1177/0961203314540353.
127. [127] Alsuwaida, A., Successful management of systemic lupus erythematosus nephritis flare-up during pregnancy with tacrolimus. Mod Rheumatol 21 (2011), 73–75, 10.1007/s10165-010-0340-4.
128. [128] Bramham, K., Chusney, G., Lee, J., et al. Breastfeeding and tacrolimus: serial monitoring in breast-fed and bottle-fed infants. Clin J Am Soc Nephrol 8 (2013), 563–567, 10.2215/CJN.06400612.
129. [129] Armenti, V.T., Constantinescu, S., Moritz, M.J., et al. Pregnancy after transplantation. Transpl Rev 22 (2008), 223–240, 10.1016/j.trre.2008.05.001.
130. [130] Avilés, A., Niz, J., Long-term follow-up of children born to mothers with acute leukemia during pregnancy. Med Pediatr Oncol 16 (1988), 3–6.
131. [131] Avilés, A., Díaz-Maqueo, J.C., Talavera, A., et al. Growth and development of children of mothers treated with chemotherapy during pregnancy: current status of 43 children. Am J Hematol 36 (1991), 243–248.
132. [132] Bazzani, C., Scrivo, R., Andreoli, L., et al. Prospectively-followed pregnancies in patients with inflammatory arthritis taking bimological drugs: an Italian multicentre study. Clin Exp Rheumatol 33 (2015), 688–693.
133. [133] Mahadevan, U., Wolf, D.C., Dubinsky, M., et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 11 (2013), 286–292, 10.1016/j.cgh.2012.11.011 quiz e24.
134. [134] Hoffman, M.B., Farhangian, M., Feldman, S.R., Psoriasis during pregnancy: characteristics and important management recommendations. Expert Rev Clin Immunol 11 (2015), 709–720, 10.1586/1744666X.2015.1037742.
135. [135] Berthelsen, B.G., Fjeldsøe-Nielsen, H., Nielsen, C.T., et al. Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. Rheumatology 49 (2010), 2225–2227, 10.1093/rheumatology/keq185.
136. [136] Carter, J.D., Ladhani, A., Ricca, L.R., et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the food and drug administration database. J Rheumatol 36 (2009), 635–641, 10.3899/jrheum.080545.
137. [137] Winger, E.E., Reed, J.L., Was risk properly assessed in Carter, et al's safety assessment of tumor necrosis factor antagonists during pregnancy?. J Rheumatol, 36, 2009, 2122, 10.3899/jrheum.090141.
138. [138] Marchioni, R.M., Lichtenstein, G.R., Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol 19 (2013), 2591–2602, 10.3748/wjg.v19.i17.2591.
139. [139] Nielsen, O.H., Loftus, E.V., Jess, T., Safety of TNF-α inhibitors during IBD pregnancy: a systematic review. BMC Med, 11, 2013, 174, 10.1186/1741-7015-11-174.
140. [140] Cheent, K., Nolan, J., Shariq, S., et al. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis 4 (2010), 603–605, 10.1016/j.crohns.2010.05.001.
141. [141] Ramsey-Goldman, R., Schilling, E., Immunosuppressive drug use during pregnancy. Rheum Dis Clin North Am 23 (1997), 149–167, 10.1016/S0889-857X(05)70320-3.
142. [142] Sanofi. Arava & Pregnancy: Counseling guidelines for women of childbearing potential. http://www.arava.com/hcp/about/pregnancy.aspx [accessed 01.04.16].
143. Chambers, C.D., Johnson, D.L., Robinson, L.K., et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum 62 (2010), 1494–1503, 10.1002/art.27358.